jama tirzepatide Ophthalmic Complications Observed After Use of GLP-1 Agonists Study comparing Mounjaro and Ozempic

In diabetes, HFpEF is predominantly driven by coronary microvascular disease/dysfunction, systemic inflammation, as well as cardiovascular autonomic dysfunction (which is very specific to diabetes) and a deficient heart oxidative metabolism, all leading to remodeling of the heart and increased stiffness, while HFrEF is predominantly driven by adverse remodeling secondary to accelerated atherosclerotic CVD (ASCVD)

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use

PMID 12729762

Take the free TrimRx assessment quiz today

So how can you get the body to generate enough and whats the best one to take